Market Research Logo

Atherosclerosis - Pipeline Review, H1 2015

Atherosclerosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2015’, provides an overview of the Atherosclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Atherosclerosis Overview
Therapeutics Development
Pipeline Products for Atherosclerosis - Overview
Pipeline Products for Atherosclerosis - Comparative Analysis
Atherosclerosis - Therapeutics under Development by Companies
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes
Atherosclerosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Atherosclerosis - Products under Development by Companies
Atherosclerosis - Products under Investigation by Universities/Institutes
Atherosclerosis - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos S/A
advanceCor GmbH
AFFiRiS AG
Arisaph Pharmaceuticals, Inc.
Artery Therapeutics, Inc.
AstraZeneca Plc
Athera Biotechnologies AB
AtheroNova Inc.
AuraSense Therapeutics, LLC
Bayer AG
Bridge Bioresearch Plc
Campus Technologies Freiburg GmbH
Cardax Pharmaceuticals, Inc.
ChemoCentryx, Inc.
CohBar Inc.
DoNatur GmbH
Dr. Reddy's Laboratories Limited
Dybly AG
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GenKyoTex S.A.
Gilead Sciences, Inc.
Isis Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
KineMed, Inc.
Kowa Company, Ltd.
Lead Discovery Center GmbH
MedImmune, LLC
Merck & Co., Inc.
MI.TO. Technology S.r.L.
Novartis AG
Omeros Corporation
OPKO Health, Inc.
Otsuka Holdings Co., Ltd.
Provid Pharmaceuticals, Inc.
Resverlogix Corp.
The Medicines Company
Therapix Biosciences Ltd
Vascular Biogenics Ltd.
Vericel Corporation
Vitae Pharmaceuticals, Inc.
Atherosclerosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
6860766 - Drug Profile
AEM-28 - Drug Profile
AG-01 - Drug Profile
AHRO-001 - Drug Profile
AHRO-002 - Drug Profile
AHRO-003 - Drug Profile
aliskiren fumarate - Drug Profile
AM-0010 - Drug Profile
anacetrapib - Drug Profile
Annexin A-5 - Drug Profile
Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis - Drug Profile
ARI-1778 - Drug Profile
Artpep-2 - Drug Profile
ATH-03 - Drug Profile
ATH-04 - Drug Profile
ATH-05 - Drug Profile
ATH-06 - Drug Profile
AZ-876 - Drug Profile
BAY-606583 - Drug Profile
BSN-272 - Drug Profile
CCX-771 - Drug Profile
CCX-872 - Drug Profile
CDX-085 - Drug Profile
Cell Therapy for Atherosclerosis - Drug Profile
CM-7 - Drug Profile
COR-2 - Drug Profile
CSN-501 - Drug Profile
CVX-210H - Drug Profile
D-4F - Drug Profile
DIAS-2 - Drug Profile
DRL-17822 - Drug Profile
Drug for Atherosclerosis - Drug Profile
Drug to Agonize TLR-4 for Metabolic Disorders, Immunology and Cardiovascular Disease - Drug Profile
Drugs for Cardiovascular Diseases - Drug Profile
Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile
DYB-186 - Drug Profile
EP-80317 - Drug Profile
evacetrapib - Drug Profile
FX-5A - Drug Profile
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile
Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile
GKT-136901 - Drug Profile
GKT-137831 - Drug Profile
GKT-901 - Drug Profile
GYY-4137 - Drug Profile
Humanin - Drug Profile
INV-88 - Drug Profile
ISIS-APOARx - Drug Profile
ixmyelocel-T - Drug Profile
JD-6000 Series - Drug Profile
K-312 - Drug Profile
K-877 - Drug Profile
KM-011 - Drug Profile
KRP-206 - Drug Profile
LDN-193189 - Drug Profile
LPC-01 - Drug Profile
MCS-18 - Drug Profile
MDCO-216 - Drug Profile
MEDI-6012 - Drug Profile
melittin - Drug Profile
microRNA-30c for Hyperlipidemia and Atherosclerosis - Drug Profile
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile
Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile
Nanotherapeutics - Drug Profile
Oligonucleotide to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile
P-16 - Drug Profile
PC-mAb - Drug Profile
Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile
Protein for Atherosclerosis - Drug Profile
Px-102 - Drug Profile
Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile
RO-6836191 - Drug Profile
rPAI-123 - Drug Profile
RVX-208 - Drug Profile
Small Molecule for Atherosclerosis - Drug Profile
Small Molecule for Atherosclerosis - Drug Profile
Small Molecule Target GPR176 for Atherosclerosis - Drug Profile
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
Small Molecule to Target GPR132 for Atherosclerosis - Drug Profile
Small Molecules for Atherosclerosis - Drug Profile
Small Molecules for Atherosclerosis - Drug Profile
Small Molecules for Inflammatory Diseases - Drug Profile
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity - Drug Profile
Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases - Drug Profile
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile
Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile
SPX-7233801 - Drug Profile
Stem Cell Therapy for Atherosclerosis - Drug Profile
SYN-20110119RU - Drug Profile
Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile
Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile
Vaccine for Atherosclerosis - Drug Profile
Vaccine for Atherosclerosis - Drug Profile
Vaccine for Atherosclerosis - Drug Profile
Vaccine to Target Angiotensin II for Cardiovascular Diseases - Drug Profile
VB-201 - Drug Profile
VTP-4 - Drug Profile
Atherosclerosis - Recent Pipeline Updates
Atherosclerosis - Dormant Projects
Atherosclerosis - Discontinued Products
Atherosclerosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Atherosclerosis, H1 2015
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015
Atherosclerosis - Pipeline by advanceCor GmbH, H1 2015
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2015
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2015
Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2015
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2015
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2015
Atherosclerosis - Pipeline by AuraSense Therapeutics, LLC, H1 2015
Atherosclerosis - Pipeline by Bayer AG, H1 2015
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H1 2015
Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H1 2015
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H1 2015
Atherosclerosis - Pipeline by CohBar Inc., H1 2015
Atherosclerosis - Pipeline by DoNatur GmbH, H1 2015
Atherosclerosis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2015
Atherosclerosis - Pipeline by Dybly AG, H1 2015
Atherosclerosis - Pipeline by Eli Lilly and Company, H1 2015
Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Atherosclerosis - Pipeline by GenKyoTex S.A., H1 2015
Atherosclerosis - Pipeline by Gilead Sciences, Inc., H1 2015
Atherosclerosis - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H1 2015
Atherosclerosis - Pipeline by Johnson & Johnson, H1 2015
Atherosclerosis - Pipeline by KineMed, Inc., H1 2015
Atherosclerosis - Pipeline by Kowa Company, Ltd., H1 2015
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2015
Atherosclerosis - Pipeline by MedImmune, LLC, H1 2015
Atherosclerosis - Pipeline by Merck & Co., Inc., H1 2015
Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H1 2015
Atherosclerosis - Pipeline by Novartis AG, H1 2015
Atherosclerosis - Pipeline by Omeros Corporation, H1 2015
Atherosclerosis - Pipeline by OPKO Health, Inc., H1 2015
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2015
Atherosclerosis - Pipeline by Resverlogix Corp., H1 2015
Atherosclerosis - Pipeline by The Medicines Company, H1 2015
Atherosclerosis - Pipeline by Therapix Biosciences Ltd, H1 2015
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H1 2015
Atherosclerosis - Pipeline by Vericel Corporation, H1 2015
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Atherosclerosis Therapeutics - Recent Pipeline Updates, H1 2015
Atherosclerosis - Dormant Projects, H1 2015
Atherosclerosis - Dormant Projects (Contd..1), H1 2015
Atherosclerosis - Dormant Projects (Contd..2), H1 2015
Atherosclerosis - Dormant Projects (Contd..3), H1 2015
Atherosclerosis - Dormant Projects (Contd..4), H1 2015
Atherosclerosis - Dormant Projects (Contd..5), H1 2015
Atherosclerosis - Dormant Projects (Contd..6), H1 2015
Atherosclerosis - Dormant Projects (Contd..7), H1 2015
Atherosclerosis - Dormant Projects (Contd..8), H1 2015
Atherosclerosis - Discontinued Products, H1 2015
Atherosclerosis - Discontinued Products (Contd..1), H1 2015
Atherosclerosis - Discontinued Products (Contd..2), H1 2015
List of Figures
Number of Products under Development for Atherosclerosis, H1 2015
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report